Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.

Melanie Jane DaviesAmra Ciric AlibegovicGayathri AnilUffe Christian BraaeAnders Boeck JensenRikke Baastrup Nordsborg

Published in: Diabetic medicine : a journal of the British Diabetic Association (2023)

Combining BIAsp 30 + GLP-1RA provides glycaemic control with no significant difference to that of propensity score-matched people receiving basal insulin+GLP-1RA, with no increase in hypoglycaemia risk or weight gain.

Keyphrases

type diabetes
weight gain
glycemic control
rheumatoid arthritis
body mass index
cardiovascular disease
birth weight
insulin resistance
disease activity
ankylosing spondylitis
metabolic syndrome
weight loss
skeletal muscle
systemic sclerosis
gestational age